Literature DB >> 11283636

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

D Lawrence, Z Shahrokh, S Marsters, K Achilles, D Shih, B Mounho, K Hillan, K Totpal, L DeForge, P Schow, J Hooley, S Sherwood, R Pai, S Leung, L Khan, B Gliniak, J Bussiere, C A Smith, S S Strom, S Kelley, J A Fox, D Thomas, A Ashkenazi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11283636     DOI： 10.1038/86397

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  146 in total

Review 1.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

Review 2.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 3.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

4.  Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.

Authors:  Perry T Yin; Shreyas Shah; Nicholas J Pasquale; Olga B Garbuzenko; Tamara Minko; Ki-Bum Lee
Journal:  Biomaterials       Date:  2015-11-12       Impact factor: 12.479

5.  Targeting death receptors: is this trail still hot?

Authors:  Rajen Mody
Journal:  Transl Pediatr       Date:  2013-04

6.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Sophia Tseleni-Balafouta; Avi Ashkenazi; Demetrios A Koutras; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 7.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

8.  Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l.

Authors:  J J Lum; A A Pilon; J Sanchez-Dardon; B N Phenix; J E Kim; J Mihowich; K Jamison; N Hawley-Foss; D H Lynch; A D Badley
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

Authors:  Leo Christopher DeRosier; Donald J Buchsbaum; Patsy G Oliver; Zhi-Qiang Huang; Jeffrey C Sellers; William E Grizzle; Wenquan Wang; Tong Zhou; Kurt R Zinn; Joshua W Long; Selwyn M Vickers
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

10.  Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.

Authors:  Kan Kondo; Seiji Yamasaki; Naoya Inoue; Tomoharu Sugie; Naoki Teratani; Takatsugu Kan; Yutaka Shimada
Journal:  Surg Today       Date:  2006       Impact factor: 2.549
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.